At Alys Pharmaceuticals, we could not be prouder to now count 2 recipients of the prestigious Marion B Sulzberger award among our co-founders, co-workers and advisors: John E. Harris, MD, PhD (2021 recipient) and Brian Kim (2024 recipient). The recipients of this award should have made significant contributions to the understanding of clinical medicine via their research: how appropriate to have you on board to bring transformative therapies forward !
About us
Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics, and has a number of strategic collaborations with leading research institutions.
- Website
-
alyspharma.com
External link for Alys Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
- Founded
- 2024
Employees at Alys Pharmaceuticals
Updates
-
Congratulations to co-founder Brian Kim for the Academy's recognition. Great lecture delivered yesterday, and huge thanks for showcasing Alys Pharmaceuticals on such a big stage: let's indeed bring your concepts and research to patients!
Thank you to the American Academy of Dermatology for the incredible honor of receiving the Marion B Sulzberger Award. I am grateful to all my mentors, colleagues, trainees, and patients for believing in the vision of how we can #transform #basic #science to new #therapies while simultaneously unveiling how #neuroimmunology will fundamentally redefine how we #diagnose #manage and #treat #patients across all medical specialties. I am grateful for the opportunity to do all this through the many stakeholders who have invested in me as a #scientist #physician #inventor #founder. Thank you The National Institutes of Health Doris Duke Foundation The Paul G. Allen Frontiers Group Paul G. Allen Family Foundation for support in the past, present, and future. Thanks to Medicxi for building Alys Pharmaceuticals to move our science into the clinic. Thanks to the leadership at Icahn School of Medicine at Mount Sinai for believing in all of this!
-
-
Special thanks to Clive Cookson and the Financial Times for covering the launch of Alys Pharmaceuticals. Chairman Francesco De Rubertis and COO Thibaud Portal spoke to Clive on the story behind Alys, from the origins of the six asset-centric subsidiary companies, to the $100M in seed financing from Medicxi and the wealth of experience and expertise among the esteemed group of co-founders and scientific leadership. With a vision to transform the treatment paradigm for several dermatology indications, Alys boasts a robust pipeline of innovative programs and platforms. Read the article here: https://lnkd.in/eawCmeue For more information on the Alys story, visit our website: alyspharma.com
-
Today, Alys Pharmaceuticals launches as an innovation leader in immuno-dermatology with $100M seed financing from Medicxi, which co-founded #Alys alongside world-leading dermatology and scientific experts. Formed through the aggregation of six-asset centric Medicxi companies, Alys boasts a robust R&D pipeline of cutting-edge programs and platforms targeting multiple dermatological indications. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics, inheriting over a dozen active programs and a confident outlook for further organic pipeline growth. Read the full press release here: bit.ly/3SUxmCd For more information on the Alys story, see our website here: alyspharma.com #dermatology #financing #innovation #dermatitis #vitiligo #alopecia
-